Regulation
Aurenar wins breakthrough designation for cerebral vasospasm neuromodulation platform
Aurenar received FDA Breakthrough Device designation for its V-Link system, a transauricular vagus nerve stimulation platform designed to modulate brain inflammation in post-stroke patients with cerebral vasospasm. The designation accelerates review pathways for the neuromodulation device.
The source
This brief is a MedIndexer summary of reporting by Medical Device Network. To read the full story, head to the source.
Read the full story at Medical Device Network